http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160008092-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_259045c6eba6e2c5d338b84e0a88b571 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-322 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L1-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4738 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4738 |
| filingDate | 2015-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8805db04ffd928002e5b6cb66e9385d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7424c874eacce687403c33613ed3ce50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15ae2444483e649befb9d6c55052d78e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64fecad7fc22e48ea759906393648665 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd6e2d1df370f2678b6f73f513130499 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce9681f9304af435aeda72e5c769471b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7792d4e9b9f5b2adf775140d521aacfb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3ebc968ebc26e7aff7a2d69d04f4b1c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fdc4c06f1a56710b52cf4b4b86e7f6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2977885865376c25c70f2e2aedfda39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_213554f45ff7ab11019bb47fe61e5562 |
| publicationDate | 2016-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20160008092-A |
| titleOfInvention | Pharmaceutical composition comprising CX-4945 for prevention or treatment of Degenerative Brain Diseases |
| abstract | The present invention relates to a process for the preparation of 5 - [(3-chlorophenyl) amino] benzo [c] -2,6-naphthyridine -8-carboxylic acid (CX-4945) as an active ingredient. More particularly, the present invention relates to a pharmaceutical composition for preventing and treating degenerative brain diseases, which comprises CX2 and Cdc2-like kinase (Clk) 4945 showed a strong inhibitory effect on Dyrk1A in vitro and inhibited DTPA in a competitive manner with ATP and strongly inhibited Dyrk1A at the cellular level, resulting in nerve fiber entanglement and Tau , Amyloid precursor protein (APP) and PS1 (presenilin 1), inhibit NFATc phosphorylation, increase transcriptional activity of NFATc, and increase the expression of wings, eyes, and nerves when the Drosophila Dyrk1A minibrain is overexpressed in the Drosophila model. It was confirmed that the neural developmental abnormality was significantly improved INDY and proINDY, which are generally used as Dyrk1A inhibitors, by confirming that the phosphorylation of Tau protein is remarkably lowered in Dyrk1A overexpressing mice. Thus, 5 - [(3-chlorophenyl) Amino] benzo [c] -2,6-naphthyridine-8-carboxylic acid (CX-4945) can be usefully used as a composition for preventing and treating degenerative brain diseases associated with Dyrk1A. |
| priorityDate | 2014-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 367.